Opus Genetics (IRD) Receivables (2012 - 2026)

Opus Genetics (IRD) has reported Receivables for 10 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables fell 43.8% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 43.8% YoY), while the FY2025 annual figure was $2.0 million, down 44.01% from the prior year.
• Receivables fell to $1.7 million in Q1 2026 per IRD's latest filing, from $2.0 million in the prior quarter.
• Across five years, Receivables topped out at $10.1 million in Q3 2023 and bottomed at $135000.0 in Q2 2023.
• Historically, Receivables has averaged $2.7 million across 5 years, with a median of $2.0 million in 2024.
• On a YoY basis, Receivables climbed as much as 905.93% in 2024 and fell as far as 81.67% in 2024.
• Opus Genetics' Receivables stood at $1.3 million in 2022, then fell by 28.66% to $926000.0 in 2023, then jumped by 284.77% to $3.6 million in 2024, then sank by 44.01% to $2.0 million in 2025, then decreased by 13.23% to $1.7 million in 2026.
• Business Quant data shows IRD's Receivables at $1.7 million in Q1 2026, $2.0 million in Q4 2025, and $2.9 million in Q3 2025.